Log In
BCIQ
Print this Print this
 

VSN16R

  Manage Alerts
Collapse Summary General Information
Company Canbex Therapeutics Ltd.
DescriptionUndisclosed antispastic oral small molecule
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationSpasticity
Indication DetailsTreat spasticity in multiple sclerosis (MS) patients
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$107.4M

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

02/24/2015

$107.4M

0

Undisclosed

Get a free BioCentury trial today